Literature DB >> 10146991

Discounting in cost-effectiveness analysis of healthcare programmes.

D A Katz1, H G Welch.   

Abstract

Discounting is a technique commonly used in cost-effectiveness analysis to 'make fair' comparisons of programmes whose costs and outcomes occur at different times. It is not a correction for inflation. While there is general agreement among health economists regarding the need to discount, there is less consensus on the procedure for discounting costs or benefits. We describe the method of constant-rate discounting, which uses the same rate to discount costs and benefits, and examine its impact on the cost effectiveness of selected health interventions. This methodology has significant limitations, however. Constant-rate discounting may not accurately represent the values of a society. Furthermore, discounting does not reflect the longitudinal time preferences of individuals (or groups). The philosophical rationale for constant-rate discounting is the concept of longitudinal equity, i.e. that society should make allocation decisions in such a way that present and future cohorts are treated equally, regardless of when they come into existence. In general, discounting affects the cost effectiveness of preventive interventions more than acute interventions, and it affects programmes with immediate cost more that those with ongoing cost. The reader of such analyses should be aware of these effects, and should use caution in comparing the cost effectiveness of interventions with vastly different timing of cost and benefit.

Mesh:

Year:  1993        PMID: 10146991     DOI: 10.2165/00019053-199303040-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

1.  Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

Authors:  D Coyle; K Tolley
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

2.  Philosophical origins of the social rate of discount in cost-benefit analysis.

Authors:  J C Robinson
Journal:  Milbank Q       Date:  1990       Impact factor: 4.911

3.  Comparing apples and oranges: does cost-effectiveness analysis deal fairly with the old and young?

Authors:  H G Welch
Journal:  Gerontologist       Date:  1991-06

4.  Challenges for cost-effectiveness research.

Authors:  M C Weinstein
Journal:  Med Decis Making       Date:  1986 Oct-Dec       Impact factor: 2.583

Review 5.  Time preference for health in cost-effectiveness analysis.

Authors:  J Lipscomb
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

6.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

  6 in total
  20 in total

Review 1.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Time preference for health gains versus health losses.

Authors:  L D MacKeigan; L N Larson; J R Draugalis; J L Bootman; L R Burns
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 4.  The economic costs of asthma: a review and conceptual model.

Authors:  K B Weiss; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

5.  The reliability of cost-utility estimates in cost-per-QALY league tables .

Authors:  S Petrou; M Malek; P G Davey
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

6.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

7.  Economic decision making in healthcare. A standard approach to discounting health outcomes.

Authors:  A L Hillman; M S Kim
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

8.  A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.

Authors:  L Garattini; R Grilli; D Scopelliti; L Mantovani
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

9.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

Review 10.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.